232 related articles for article (PubMed ID: 27154346)
21. Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces.
Benbouziane B; Ribelles P; Aubry C; Martin R; Kharrat P; Riazi A; Langella P; Bermúdez-Humarán LG
J Biotechnol; 2013 Oct; 168(2):120-9. PubMed ID: 23664884
[TBL] [Abstract][Full Text] [Related]
22. Recombinant lactic acid bacteria as promising vectors for mucosal vaccination.
Qiao N; Du G; Zhong X; Sun X
Exploration (Beijing); 2021 Oct; 1(2):20210026. PubMed ID: 37323212
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in microparticle and nanoparticle delivery vehicles for mucosal vaccination.
McNeela EA; Lavelle EC
Curr Top Microbiol Immunol; 2012; 354():75-99. PubMed ID: 21904984
[TBL] [Abstract][Full Text] [Related]
24. A review of food-grade vectors in lactic acid bacteria: from the laboratory to their application.
Landete JM
Crit Rev Biotechnol; 2017 May; 37(3):296-308. PubMed ID: 26918754
[TBL] [Abstract][Full Text] [Related]
25. Engineering of lactic acid bacteria for delivery of therapeutic proteins and peptides.
Plavec TV; Berlec A
Appl Microbiol Biotechnol; 2019 Mar; 103(5):2053-2066. PubMed ID: 30656391
[TBL] [Abstract][Full Text] [Related]
26. Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles.
Srivastava A; Gowda DV; Madhunapantula SV; Shinde CG; Iyer M
APMIS; 2015 Apr; 123(4):275-88. PubMed ID: 25630573
[TBL] [Abstract][Full Text] [Related]
27. Live bacterial delivery systems for development of mucosal vaccines.
Thole JE; van Dalen PJ; Havenith CE; Pouwels PH; Seegers JF; Tielen FD; van der Zee MD; Zegers ND; Shaw M
Curr Opin Mol Ther; 2000 Feb; 2(1):94-9. PubMed ID: 11249657
[TBL] [Abstract][Full Text] [Related]
28. Heterologous protein production and delivery systems for Lactococcus lactis.
Nouaille S; Ribeiro LA; Miyoshi A; Pontes D; Le Loir Y; Oliveira SC; Langella P; Azevedo V
Genet Mol Res; 2003 Mar; 2(1):102-11. PubMed ID: 12917806
[TBL] [Abstract][Full Text] [Related]
29. Novel applications of recombinant lactic acid bacteria in therapy and in metabolic engineering.
Berlec A; Strukelj B
Recent Pat Biotechnol; 2009; 3(2):77-87. PubMed ID: 19519564
[TBL] [Abstract][Full Text] [Related]
30. Targeting mucosal dendritic cells with microbial antigens from probiotic lactic acid bacteria.
Mohamadzadeh M; Duong T; Hoover T; Klaenhammer TR
Expert Rev Vaccines; 2008 Mar; 7(2):163-74. PubMed ID: 18324887
[TBL] [Abstract][Full Text] [Related]
31. Potential and opportunities for use of recombinant lactic acid bacteria in human health.
Hanniffy S; Wiedermann U; Repa A; Mercenier A; Daniel C; Fioramonti J; Tlaskolova H; Kozakova H; Israelsen H; Madsen S; Vrang A; Hols P; Delcour J; Bron P; Kleerebezem M; Wells J
Adv Appl Microbiol; 2004; 56():1-64. PubMed ID: 15566975
[No Abstract] [Full Text] [Related]
32. Current issues regarding the application of recombinant lactic acid bacteria to mucosal vaccine carriers.
Takahashi K; Orito N; Tokunoh N; Inoue N
Appl Microbiol Biotechnol; 2019 Aug; 103(15):5947-5955. PubMed ID: 31175431
[TBL] [Abstract][Full Text] [Related]
33. Mucosal delivery of vaccines in domestic animals.
Gerdts V; Mutwiri GK; Tikoo SK; Babiuk LA
Vet Res; 2006; 37(3):487-510. PubMed ID: 16611560
[TBL] [Abstract][Full Text] [Related]
34. Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes.
Pouwels PH; Leer RJ; Shaw M; Heijne den Bak-Glashouwer MJ; Tielen FD; Smit E; Martinez B; Jore J; Conway PL
Int J Food Microbiol; 1998 May; 41(2):155-67. PubMed ID: 9704864
[TBL] [Abstract][Full Text] [Related]
35. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines.
He Q; Martinez-Sobrido L; Eko FO; Palese P; Garcia-Sastre A; Lyn D; Okenu D; Bandea C; Ananaba GA; Black CM; Igietseme JU
Immunology; 2007 Sep; 122(1):28-37. PubMed ID: 17451464
[TBL] [Abstract][Full Text] [Related]
36. Main Features of DNA-Based Vectors for Use in Lactic Acid Bacteria and Update Protocols.
Coelho-Rocha ND; Barroso FAL; Tavares LM; Dos Santos ESS; Azevedo V; Drumond MM; Mancha-Agresti P
Methods Mol Biol; 2021; 2197():285-304. PubMed ID: 32827144
[TBL] [Abstract][Full Text] [Related]
37. Recent developments in mucosal delivery of pDNA vaccines.
Barnes AG; Barnfield C; Brew R; Klavinskis LS
Curr Opin Mol Ther; 2000 Feb; 2(1):87-93. PubMed ID: 11249656
[TBL] [Abstract][Full Text] [Related]
38. Needle-free vaccine delivery.
Giudice EL; Campbell JD
Adv Drug Deliv Rev; 2006 Apr; 58(1):68-89. PubMed ID: 16564111
[TBL] [Abstract][Full Text] [Related]
39. Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery.
Wang SH; Thompson AL; Hickey AJ; Staats HF
Curr Top Microbiol Immunol; 2012; 354():121-56. PubMed ID: 21822816
[TBL] [Abstract][Full Text] [Related]
40. From physiology to systems metabolic engineering for the production of biochemicals by lactic acid bacteria.
Gaspar P; Carvalho AL; Vinga S; Santos H; Neves AR
Biotechnol Adv; 2013 Nov; 31(6):764-88. PubMed ID: 23567148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
